DUBLIN–(BUSINESS WIRE)–The “Direct-acting Antiviral Drug Market Research Report by Type (NS3/4A Protease, NS5A Protein, and NS5B RNA-Dependent RNA polymerase), Indication, Route, Distribution Channel, State – United States Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering.
The United States Direct-acting Antiviral Drug Market size was estimated at USD 1,676.39 million in 2021, USD 2,013.27 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 15.62% to reach USD 4,005.91 million by 2027.
Key Topics Covered:
1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Cumulative Impact of COVID-19
6. Direct-acting Antiviral Drug Market, by Type
6.1. Introduction
6.2. NS3/4A Protease
6.3. NS5A Protein
6.4. NS5B RNA-Dependent RNA polymerase
7. Direct-acting Antiviral Drug Market, by Indication
7.1. Introduction
7.2. HIV Infection/ AIDS
7.3. Hepatitis C Virus
7.4. Influenza
7.5. Prophylaxis
8. Direct-acting Antiviral Drug Market, by Route
8.1. Introduction
8.2. Intravenous
8.3. Oral
8.4. Subcutaneous
8.5. Topical
9. Direct-acting Antiviral Drug Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Drug Store
9.4. Retail Pharmacy
10. California Direct-acting Antiviral Drug Market
11. Florida Direct-acting Antiviral Drug Market
12. Illinois Direct-acting Antiviral Drug Market
13. New York Direct-acting Antiviral Drug Market
14. Ohio Direct-acting Antiviral Drug Market
15. Pennsylvania Direct-acting Antiviral Drug Market
16. Texas Direct-acting Antiviral Drug Market
17. Competitive Landscape
17.1. FPNV Positioning Matrix
17.2. Market Ranking Analysis
17.3. Market Share Analysis, By Key Player
17.4. Competitive Scenario
18. Company Usability Profiles
Companies Mentioned
- A-S Medication Solutions
- Actavis Group Ptc Ehf.
- Agouron Pharmaceuticals
- Aizant Drug Research Solutions Pvt Ltd
- Amneal Pharmaceuticals LLC
- Apotex Corporation
- Atea Pharmaceuticals, Inc.
- Auro Pharma Inc
- Boehringer Ingelheim Pharmaceuticals Inc.
- Bristol-Myers Squibb Company
- Camber Pharmaceuticals, Inc.
- Cipla USA Inc.
- E.R. Squibb & Sons, L.L.C.
- F. Hoffmann-La Roche
- Genentech, Inc.
- H.J. Harkins Company
- Jamp Pharma Corporation
- Marcan Pharmaceuticals Inc
- Merck Ltd.
- Mylan N.V.
- New American Therapeutics, Inc
- Novartis
- PD-Rx Pharmaceuticals, Inc.
- Pfizer Inc.
- Physicians Total Care, Inc.
- Prestium Pharma, Inc.
- Remedy Repack
- Sciegen Pharmaceuticals Inc.
- Teva Pharmaceuticals USA, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/capjn3
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
